Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See
full details
.
I Agree
×
Join today and have your say! It’s FREE!
Join Now
Sign In
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
Join Today
or
Sign in with existing account
Privacy Policy
|
Disclaimer
Sign In
Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Remember me
Forgot Password?
Sign In
or
Sign Up
Privacy Policy
|
Disclaimer
Please Try Again
{{ error }}
Send my password
Submit
Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Linking with Facebook:
Stockhouse membership requires an email address which must be shared by Facebook.
By default, joining or signing in using your Facebook account will work and the email address will be shared by Facebook automatically.
If you change your Facebook permissions to restrict Stockhouse from receiving your email while joining or signing in to Stockhouse then it will fail.
Please do not modify the permission settings during sign-in.
Sign in with Facebook
Return to Signup Options
Home
Community
Bullboards
Blogs
Groups
Messages
Markets
Stocks
TSX
TSXV
CSE
Cboe Canada
NASDAQ
NYSE
NYSE American
Cryptocurrency
Currencies
Market Movers
Bonds
News
Featured News
Trending News
Canadian Press Releases
US Press Releases
Video
Editorial
Thematic Insights
Independent Reports
Interviews
Buzz on the Bullboards
Portfolio
Watchlist
Portfolio
Showcase Companies
DealRoom
News Focus
LQWD Technologies Lightning Network Infrastructure Surpasses 1 Million Global Transactions (click to learn more)
Quote
|
Bullboard
|
News
|
Opinion
|
Profile
|
Peers
|
Filings
|
Financials
|
Options
|
Price History
|
Ratios
|
Ownership
|
Insiders
|
Valuation
Bullboard - Stock Discussion Forum
Oncolytics Biotech Inc
T.ONC
Alternate Symbol(s):
ONCY
Healthcare
Biotechnology
Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and...
adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.
see more
Join the community and start posting on the bullboards today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Create a portfolio watchlist today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Add To Watchlist
Bullboard (TSX:ONC)
New Post
View:
Posts & Comments
Threaded Posts
Prev
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
...
Next
(931)
•••
canadafan
X
View Profile
View Bullboard History
Post by
canadafan
on Nov 11, 2024 3:57pm
Shorting analysis, risk
Obviously, a few on here are shorting. Looking at the upside. They have fast track approval for both MBc & pancreatic cancer. A $5 million grant to add an additional arm, from PanCan
...more
(206)
•••
Buckhenry
X
View Profile
View Bullboard History
Comment by
Buckhenry
on Nov 11, 2024 3:11pm
RE:RE:RE:RE:Notice of Conference Call the Day Before
Would not put much stock here.... the company is so haphazard
Pharmaceutical Tech Co Reports 2.7X Revenue Growth Year-Over-Year at US $24 Million
posted Nov 21, 2024 9:00am by
Innocan Pharma Corp
-
|
"Our strong operational and financial momentum continued throughout 2024 and now in the third quarter, we again demonstrated solid financial results. We are pleased to report nine consecutive quarters of continuous revenue growth. Our online platform continues to perform exceptionally well, contributing to our strong nine-month revenue growth of 174% YoY ...read more
(185)
•••
CMHarring218431
X
View Profile
View Bullboard History
Comment by
CMHarring218431
on Nov 11, 2024 2:14pm
RE:RE:RE:RE:Notice of Conference Call the Day Before
Are you following me
(15)
•••
Investor5876
X
View Profile
View Bullboard History
Comment by
Investor5876
on Nov 11, 2024 2:05pm
RE:RE:RE:Notice of Conference Call the Day Before
There is a good chance that a news release will come at the end of trading today announcing a partnership. It is certainly unusal for ONC to issue notificaion of quarterly earnings only one day
...more
(206)
•••
Buckhenry
X
View Profile
View Bullboard History
Comment by
Buckhenry
on Nov 11, 2024 2:00pm
RE:RE:RE:Notice of Conference Call the Day Before
It was probably just gas...
(5316)
•••
Noteable
X
View Profile
View Bullboard History
Comment by
Noteable
on Nov 11, 2024 1:04pm
RE:“Second mouse gets the cheese “
ONCY needs to begin emphasizing in its PR that: ONCY has 5 indications that are Phase 2/3 / Accelerated Approval ready. These 5 indications with pelareorep are: (1) HR+/HER2 negative metastatic
...more
(185)
•••
CMHarring218431
X
View Profile
View Bullboard History
Comment by
CMHarring218431
on Nov 11, 2024 1:00pm
RE:RE:Notice of Conference Call the Day Before
Well .... I think something of substance was consummated on Friday , given the early Monday morning announcement, and not just some clinical details. Now, aligned with some positive news from the FDA
...more
(206)
•••
Buckhenry
X
View Profile
View Bullboard History
Comment by
Buckhenry
on Nov 11, 2024 12:55pm
RE:RE:RE:RE:RE:Notice of Conference Call the Day Before
I get tickled reading all the pumpers visions of sugar plums dancing in their empty heads. Read this same of stuff the last 5 years. Nothing concrete here. But please be patient and remember
...more
(5316)
•••
Noteable
X
View Profile
View Bullboard History
Comment by
Noteable
on Nov 11, 2024 12:26pm
RE:RE:RE:RE:RE:RE:RE:RE:Notice of Conference Call the Day Before
Correction - US$2.678 Billion market cap.
(5316)
•••
Noteable
X
View Profile
View Bullboard History
Comment by
Noteable
on Nov 11, 2024 12:25pm
RE:RE:RE:RE:RE:RE:RE:Notice of Conference Call the Day Before
The bottom-line is that ONCY has at least 6-8x more to offer than CGON's US$2.9 Billion market cap on a single indication with a intravesically delivered drug..
(5316)
•••
Noteable
X
View Profile
View Bullboard History
Comment by
Noteable
on Nov 11, 2024 12:14pm
RE:RE:RE:RE:RE:RE:Notice of Conference Call the Day Before
ONCY needs to begin emphasizing (listing) that: ONCY has 5 indications that are Phase 2/3 / Accelerated Approval ready. These 5 indications with pelareorep are: (1) HR+/HER2 negative metastatic
...more
(931)
•••
canadafan
X
View Profile
View Bullboard History
Comment by
canadafan
on Nov 11, 2024 12:12pm
RE:Notice of Conference Call the Day Before
First point, they are a week late from normal/ historical practice.for the Q3 results etc. That could be 100% meaningless. Or could be delayed from on- going business talks. Secind point: Onc as
...more
(5316)
•••
Noteable
X
View Profile
View Bullboard History
Comment by
Noteable
on Nov 11, 2024 11:55am
RE:RE:RE:RE:RE:Notice of Conference Call the Day Before
A buyout offer would not be announced in concert with quarterly report.
(185)
•••
CMHarring218431
X
View Profile
View Bullboard History
Comment by
CMHarring218431
on Nov 11, 2024 11:53am
RE:RE:RE:RE:Notice of Conference Call the Day Before
Please let it be a large buyout offer. Volume toward the end of the day might indicate that it is more than a change in corporate management In the meantime, if you know a veteran take time
...more
Prev
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
...
Next
Thank You
Your Report has been submitted.
Report Abusive Content
×
Close
Sign up to get access
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
The Market Update
{{currentVideo.title}}
{{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >
A daily snapshot of everything
from market open to close.
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}
{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >
Featured News Links
Discover Options Trading Strategies to Minimize your Tax Burden